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Background: Previous reports have demonstrated that L1cam is aberrantly expressed in various tumors. The
potential role of L1cam in the progression and metastasis of gastric cancer is still not clear and needs exploring.
Methods: Expression of L1cam was evaluated in gastric cancer tissues and cell lines by immunohistochemistry and
Western blot. The relationship between L1cam expression and clinicopathological characteristics was analyzed. The
effects of L1cam on cell proliferation, migration and invasion were investigated in gastric cancer cell lines both
in vitro and in vivo. The impact of L1cam on PI3K/Akt pathway was also evaluated.
Results: L1cam was overexpressed in gastric cancer tissues and cell lines. L1cam expression was correlated with
aggressive tumor phenotype and poor overall survival in gastric cancer patients. Ectopic expression of L1cam in
gastric cell lines significantly promoted cell proliferation, migration and invasion whereas knockdown of L1cam
inhibited cell proliferation, migration and invasion in vitro as well as tumorigenesis and metastasis in vivo. The low
level of phosphorylated Akt in HGC27 cells was up-regulated after ectopic expression of L1cam, whereas the high
level of phosphorylated Akt in SGC7901 cells was suppressed by knockdown of L1cam. Moreover, the migration
and invasion promoted by L1cam overexpression in gastric cancer cells could be abolished by either application of
LY294002 (a phosphoinositide-3-kinase inhibitor) or knockdown of endogenous Akt by small interfering RNA.
Conclusions: Our study demonstrated that L1cam, overexpressed in gastric cancer and associated with poor
prognosis, plays an important role in the progression and metastasis of gastric cancer.
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Gastric cancer is the fourth most common malignancy
and second leading cause of cancer-related mortality
worldwide [1]. Although it is curable if detected early,
most patients are diagnosed at advanced stage and have
poor prognosis [2]. Tumor invasion and metastasis are
critical steps in determining aggressive tumor phenotype
and also constitute the main causes of cancer-related
deaths [3]. Because traditional methods do not allow* Correspondence: xurh@sysucc.org.cn
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reproduction in any medium, provided the orprecise prediction of tumor progression and metastasis for
patients after surgical resection of the primary tumor, there
is an urgent need to identify new molecules that associated
with gastric cancer progression and metastasis [4].
L1cam is a 220 kDa multidomain type 1 membrane
glycoprotein that belongs to the neuronal immunoglobulin
superfamily of cell surface molecules [5]. L1cam contains
six IgG-like and five fibronectin-type III domains in
the extracellular region, a transmembrane region and
a short intracellular cytoplasmic tail [6,7]. L1cam was
first described as a neural cell adhesion molecule and
has been shown to play an important role in cerebellar cell
motility and development of the nervous system as well as
neural growth and regeneration [8-10]. Besides neural
cells, L1cam is found to be normally expressed in othertd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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crypt cells and myelomonocytic cells [11-13]. Recent
reports found L1cam is also expressed in various tumor
cells, including colorectal cancer, renal cell carcinoma,
ovarian cancer, anaplastic thyroid carcinoma, malignant
glioma, recurrent neuroblastoma and cutaneous malig-
nant melanoma, and its expression is associated with
tumor progression and invasion [14-20]. Studies have
demonstrated that L1cam is able to stimulate many
cellular activities via homophilic biding to the extracellular
domains of the cells and heterophilic biding to other
cell adhesion proteins, integrins, extracellular matrix
molecules and cell surface receptors [21-23]. Ectopic
expression of L1cam could promote tumor cell prolifera-
tion, migration and invasion in several types of cancer,
including colon cancer, intrahepatic cholangiocarcinoma,
and gallbladder carcinoma [24-26]. In gastric cancer,
Kodera et al. reported L1cam was associated with progno-
sis of pT3-stage patients [27]. However, the biological role
and underlying molecular mechanism of L1cam in gastric
cancer progression and metastasis is still not known.
Akt (also known as Protein Kinase B) is a serine/threo-
nine-specific protein kinase, which functions as a hub
gene to integrate with different cellular signaling pathways
[28]. Threonine 308 and serine 473 (two specific amino
acid residues of Akt) can be phosphorylated upon full
activation of Akt; Akt signaling has been shown to
regulate multiple cellular activities, including cell cycle,
cell growth, cell proliferation, cell migration/invasion and
cell metabolism [29,30]. Activation of Akt signaling
pathway has been found to be involved in tumor growth
and invasion of some malignant disease [15,25]. However,
it is still unknown whether L1cam can activate Akt and
promote tumor growth and metastasis in gastric cancer.
In this study, we found L1cam was overexpressed in
gastric cancer tissues and cell lines. Expression of L1cam
was associated with clinicopathological characteristics and
prognosis in gastric cancer patients. Knockdown of L1cam
in gastric cancer cell lines significantly reduced cell prolifer-
ation, migration and invasion in vitro and suppressed
tumorigenesis and metastasis in an experimental nude
mouse model. Conversely, ectopic expression of L1cam in
gastric cells significantly promoted these activities. More-
over, we found that the PI3K/Akt pathway was involved in
the L1cam promoted cell proliferation, migration and
invasion. These results suggest L1cam plays an important
role in the progression and metastasis of gastric cancer and
could be used as a new therapeutic target.
Results
L1cam is overexpressed in gastric cancer cell lines and
tissues
L1cam mRNA expression was higher in all five gastric
cancer cell lines compared with normal gastric cancermucosa (Figure 1A). Western blot analysis confirmed
overexpression of L1cam in all gastric cancer cell lines
(Figure 1B). In matched primary gastric cancer tissues and
adjacent normal tissues, the expression of L1cam mRNA
was up-regulated by more than 1.5 fold in 19 of 30 (63%)
cancer tissues than that of normal tissues (Figure 1C).
Western blot showed overexpression of L1cam in 23 of 30
(76%) cancer tissues compared with adjacent normal
tissues (Figure 1D).
Overexpression of L1cam is associated with poor
prognosis in gastric cancer
To evaluate the clinicopathological significance of L1cam
in gastric cancer, immunohistochemistry analysis was
performed in 156 gastric cancer samples. As shown in
Figure 2A, L1cam protein was mainly located in the
cytoplasm and cell membrane of tumor cells. Positive
staining was observed in 114 of 156 (73%) cases. The
patients were divided into the L1cam low expression group
(n = 85) and the L1cam high expression group (n = 71)
based on IHC scores. The correlation between L1cam
expression and clinicopathological characteristics was
listed in Table 1. High expression of L1cam was positively
associated with large tumor size (P = 0.001), lymph node
invasion (P = 0.007), peritoneal dissemination (P = 0.019),
liver metastasis (P = 0.013) and TNM stage (P = 0.002).
Kaplan-Meier analysis with log-rank test was performed to
assess the prognostic significance of L1cam in gastric
cancer. A significant difference of overall survival was
found between patients with high L1cam expression and
patients with low L1cam expression. Kaplan-Meier survival
curves showed high L1cam expression was associated with
poor overall survival (P < 0.001, Figure 2B-D, Table 1).
Univariate analysis demonstrated patients with high L1cam
expression tended to have a higher risk of death
(HR = 2.73, 95% CI, 1.76-4.25; P < 0.001, Table 2). In
addition, other parameters including tumor size,
lymph node invasion and TNM stage were proved to
be associated with overall survival as indicated by
univariate analysis (Table 2). However, age, gender,
differentiation status and therapeutic strategy had no
prognostic significance in this studied population (Table 2,
Additional file 1: Figure S1). Multivariate analysis showed
only L1cam expression was an independent prognostic
factors for gastric cancer patients (P = 0.022, Table 2).
L1cam promotes gastric cancer cell proliferation,
migration and invasion in vitro
Based on the data listed above, we further evaluated the
role of L1cam in cell proliferation, migration and invasion.
The HGC27 cell line, which had relative low expression of
L1cam, was transfected with a pcDNA3.1(+)-L1cam
plasmid to overexpress L1cam. Another gastric cancer
cell line SGC7901 that expressed relative high level of
Figure 1 L1cam is overexpressed in gastric cancer cell lines and primary tumor tissues. (A) L1cam mRNA expression levels in gastric
cancer cell lines compared with normal gastric cancer tissue, (*P < 0.005). (B) L1cam protein expression in gastric cancer cell lines and normal
gastric cancer tissue. (C) L1cam mRNA expression levels in 30 paired gastric cancer tissues and adjacent non-cancerous tissues. (D) L1cam protein
expression level in paired gastric cancer tissues and adjacent non-cancerous tissues (the representative ones are shown).
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short hairpin RNAs (shRNA) targeting L1cam to
knockdown endogenous L1cam expression. The effect
of ectopic expression and knockdown of L1cam in
cells was confirmed by Western blot (Figure 3A).
MTT assay showed that ectopic expression of L1cam
could significantly promote the proliferative ability in
HGC27 cells as compared with control cells (P < 0.05,
Figure 3B). Similarly, colony formation capacity was
increased after overexpression of L1cam (P < 0.05,
Figure 3C). Conversely, knockdown of L1cam inhibited
growth capacity in SGC7901 cells as indicated by the
MTT and colony formation assays (P < 0.05, Figure 3B
and C). Cell motility was measured by the migration and
invasion assay. Compared with that of control cells, the
migration and invasion ability were markedly stimulated
in HGC27 cells that overexpressing L1cam (P < 0.05,
Figure 3D and E). Likewise, Knockdown of L1cam could
apparently repress the migration and invasion of SGC7901
cells (P < 0.05, Figure 3D and E).
L1cam affects the responsiveness to oxaliplatin in gastric
cancer cells
In order to determine if L1cam could affect apoptosis
and the responsiveness to anti-cancer drugs in gastric
cancer cells, firstly, we analyzed the effect of L1cam on
the apoptosis of gastric cancer cells, the results showed
that overexpression or knockdown of L1cam had no
significant effect on the apoptosis rate in gastric cancercells (Figure 4A and B); then cells were treated with
different concentrations of oxaliplatin, the results
showed that knockdown of L1cam could improve the
responsiveness to oxaliplatin in SGC7901 cells while
overexpression of L1cam could reduce the apoptosis rate
in HGC27 cells (P < 0.05, Figure 4A and B).
L1cam promotes tumorigenesis and metastasis of gastric
cancer cells in vivo
To analyze the in vivo effects of L1cam on gastric cancer
cells, we constructed two stable cell lines by using the
lentivirus vector to mediate the knockdown of L1cam
in SGC7901 cells; the resulting cells were designated
as SGC7901/scramble and SGC7901/sh-L1cam cells
respectively.
These two cell lines were injected into the left and
right flanks of each nude mouse respectively. Tumor size
was measured over time; after five weeks, mice were
sacrificed and tumors were dissected out. The results
showed that tumor growth was significantly inhibited in
SGC7901/sh-L1cam cells as compared with that of
SGC7901/scramble cells (P < 0.05, Figure 5A). In addition
to the difference in tumor volume, we also found tumor
tissues formed by injection of SGC7901/scramble cells
displayed much stronger staining of L1cam and Ki-67, as
detected by immunohistochemical analysis (Figure 5B). To
explore the effect of L1cam on in vivo tumor metastasis,
the two cell lines were injected into the tail vein of nude
mice. Six weeks later, mice were sacrificed and lung and
Figure 2 The prognostic significance of L1cam in gastric cancer patients. (A) Representative photos of L1cam expression in 156 gastric
cancer patients, a, negative staining of L1cam in adjacent normal tissues; b, weak staining of L1cam in well differentiated gastric cancer tissues; c,
moderate staining of L1cam in cancer tissues; d, strong staining of L1cam in cancer tissues, amplification (×100). (B) Kaplan-Meier analysis of
overall survival based on L1cam expression in all 156 patients. (C) and (D) Kaplan-Meier analysis of overall survival based on L1cam expression in
stage I-II (C) and stage III-IV gastric cancer patients (D).
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in vitro results, the incidences of metastasis to lung and
liver were significantly less in mice injected with SGC7901/
sh-L1cam cells than those of SGC7901/scramble cells
(P < 0.05, Figure 5C). These data suggest knockdown
of L1cam could also inhibit the tumor growth and
metastasis of gastric cancer cells in vivo.PI3K/Akt signal pathway is involved in L1cam mediated
cellular activity
Relative high expression of L1cam was found in SGC7901
and AGS cells. Knockdown of L1cam dramatically
decreased total phosphorylated Akt but not total Akt in
SGC7901 and AGS cells (Figure 6A). Ectopic expression of
L1cam in HGC27 and MKN28 cells significantly increased
Table 1 Correlations between L1cam expression and










< 60 97 57(67) 40(56)
≥ 60 59 28(33) 31(44)
Gender 0.342
Male 106 55(64) 51(72)
Female 50 30(36) 20(28)
Tumor size 0.001a
<5 cm 101 65(76) 36(51)
≥5 cm 55 20(24) 35(49)
Differentiation status 0.290
Well 9 7(8) 2(3)
Moderate 87 48(56) 39(55)
Poor and others 60 30(36) 30(42)
Lymph node invasion 0.007a
Absent 69 46(54) 23(32)
Present 87 39(46) 48(68)
Venous invasion 0.077
Absent 91 55(65) 36(51)
Present 65 30(35) 35(49)
Peritoneal dissemination 0.019a
Absent 123 73(86) 50(70)
Present 33 12(14) 21(30)
Liver metastasis 0.013a
Absent 114 69(81) 45(63)
Present 42 16(19) 26(37)
TNMb stage 0.002a
I-II 48 35(41) 13(18)
III-IV 108 50(59) 58(82)
Therapeutic strategy 0.489
Surgery only 86 49(58) 37(52)
Surgery + Chemotherapy 70 36(42) 34(48)
Survival status < 0.001a
Alive 72 52(61) 20(28)
Dead 84 33(39) 51(72)
aP < 0.05, Chi-square test.
bTNM, T, tumor; N, lymph node; M, distant metastasis.
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(Figure 6A); this effect could be abolished upon treatment
of the phosphoinositide-3-kinase inhibitor LY294002
(Figure 6B). In addition, the stimulation of cell migration
and invasion caused by ectopic expression of L1cam couldalso be suppressed by LY294002 administration (Figure 6C).
Similarly, the up-regulation of total Akt and phospho-Akt
caused by ectopic expression of L1cam in HGC27 cells
could be counteracted by knockdown of Akt using siRNA
(Figure 6D); the effect on cellular motility caused by
L1cam overexpression was also inhibited upon silencing of
Akt (Figure 6E). Moreover, treatment of LY294002 in
SGC7901 cells could significantly inhibit tumor growth in
nude mice (Figure 6F), and the expression of phospho-Akt
was reduced in tissues formed by cells that knockdown of
L1cam or treated with LY294002 (Figure 6G). These
results demonstrated that PI3K/Akt signaling was
involved in L1cam stimulated cell growth and motility
in gastric cancer cells.
Discussion
In this study, we found that both L1cam mRNA and
protein level was increased in gastric cancer cells and
tissues. L1cam was detected in 73% of the tissues from
gastric cancer patients by using IHC. Previously, Kodera
et al. reported that L1cam was expressed in 21% of the
specimens [27], but this study included p-T3 stage
patients only, thus the inconsistency might be due to
ethnic difference and difference in tumor stage. Moreover,
expression of L1cam was significantly correlated with
aggressive tumor characteristics (tumor size, lymph node
invasion, peritoneal dissemination, liver metastasis and
TNM stage) and poor prognosis; when the patients were
subdivided into two groups according to tumor stage, we
found L1cam could better distinguish patients with different
outcomes in stage III-IV than in stage I-II patients, however,
this might be due to the limited subjects in stage I-II.
Multivariate analysis demonstrated that L1cam expression
was an independent prognostic factor for gastric cancer
patients. These observations suggested that overexpression
of L1cam might be a common incidence in gastric cancer
and could serve as an independent prognostic indicator to
identify patients with different outcomes. In line with our
study, up-regulation of L1cam was also found in other
tumors, such as ovarian cancer, colorectal cancer, anaplastic
thyroid carcinoma and intrahepatic cholangiocarcinoma
[14,16,17,25]. However, further study is needed to
confirm if L1cam could be used as a universal biomarker
of prognosis for neoplasm.
As L1cam expression was associated with aggressive
tumor phenotype in gastric cancer, we speculated that
L1cam might play an important role in tumor biology.
Indeed, knockdown of endogenous L1cam expression
significantly inhibited cell proliferation, migration and
invasion, whereas ectopic expression of L1cam enhanced
these capacities. This is in line with previous studies
that highlighted the role of L1cam in progression and
metastasis of a variety of tumor types, such as uterine
and ovarian carcinoma, human malignant melanoma,
Table 2 Univariate and multivariate analysis of various potential prognostic factors in gastric cancer patients
Factors Univariate analysis Multivariate analysis
Case NO. HRb(95% CIc) P HRb(95% CIc) P
Age (<60/≥60) 87/69 0.94(0.61-1.44) 0.785 - -
Gender (male/female) 106/50 1.17(0.74-1.84) 0.511 - -
Differentiation (well, moderate/poor) 77/79 0.79(0.46-1.74) 0.381 - -
Therapeutic strategyd(Sur/Sur + Chemo) 86/70 1.21(0.79-1.86) 0.377 - -
Tumor size (≥5 cm/<5 cm) 105/51 2.27(1.54-3.37) 0.001a 1.73(0.99-3.03) 0.055
Lymph node invasion (present/absent) 111/45 1.55(1.25-1.92) 0.012a 1.05(0.73-1.53) 0.780
TNM stage (III-IV/I-II) 108/48 1.95(1.48-2.55) 0.001a 1.36(0.81-2.31) 0.249




dSur, Surgery only, Sur + Chemo: Surgery plus adjuvant Chemotherapy.
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reported that L1cam could bind to a variety of
integrins, form a protein-protein complex and activate
several signaling pathways to promote cell adhesion
and motility [37]; these L1cam/integrin-mediated
signaling transduction may also integrate with growth
factor signaling networks to stimulate cellular motility [37].
In addition, L1cam enables endocytosis of integrins by
tumor cells, thus reducing cell adhesion to the extracellular
matrix and promoting cell migration [38]. In the present
study, in order to see whether L1cam can interact with
integrins to promote cell motility in gastric cancer cells,
SGC7901 cells as well as HGC27 cells overexpressing
L1cam were treated with siRNAs against integrins
(β1, α5β1, αvβ3 and αvβ5 integrins) that have been
reported to be involved in L1cam mediated cellular activ-
ities. However, no significant effect on cellular proliferation
and invasion was observed upon administration of these
siRNAs. This is different from the results in some other
tumors, for example, L1cam stimulated cell invasion by
regulating FAK activation, possibly through interaction with
integrin receptors after ADAM10 shedding in human
glioma [39]; likewise, integrins are essential for
L1cam-mediated NF-kappaB activation and cellular
motility and invasiveness in pancreatic adenocarcinoma
and breast cancer cells [40,41]. However, further study is
needed to investigate the interaction of L1cam and
integrins in gastric cancer cells.
Given that L1cam can promote gastric cancer cell
proliferation, migration and invasion in vitro, we further
investigated the in vivo effect of L1cam. To our interest,
knockdown of L1cam by lentiviral-mediated short
hairpin RNA (shRNA) interference significantly suppressed
tumor growth and distant metastasis to lung and liver. This
is in line with previous study that targeting L1cam
decreased tumor growth and increased tumor-bearingsurvival in glioma and Cholangiocarcinoma [25,42].
Besides, L1cam monoclonal antibodies have been shown to
reduce in vivo tumor growth of several types of cancer cells
in mouse xenograft models, including ovarian cancer,
colon carcinoma and intrahepatic Cholangiocarcinoma
[25,43-45]. In this study, we also found that L1cam could
affect the responsiveness to oxaliplatin in gastric cancer
cells. In line with our results, it has been found that L1cam
conferred anti-apoptotic protection and chemoresistance
in pancreatic ductal adenocarcinoma cells [46]; moreover,
a recent study demonstrated that inhibiting L1cam by
using L1cam antibodies could increase the apoptotic
response of tumor cells towards cytostatic drugs in pancre-
atic and ovarian carcinoma [47]. These results raise the
possibility that L1cam could be used as a therapeutic target
and L1cam antibodies might serve as chemosensitizers for
malignant disease, including gastric cancer.
Recent studies have revealed that L1cam is
involved in several signal pathways. For example, the
Wnt/β-catenin/TCF pathway was found to induce
the expression of L1cam in advanced colon cancer
[36]. Ectopic expression of L1cam in ovarian carcinoma
cells activates Erk and FAK signal pathways to promote
cellular migration, invasion and apoptosis resistance
[48,49]. In human glioma, L1cam stimulated cell motility
via binding to integrin receptors, activating FAK, and
increasing turnover of focal complexes [39]. L1cam
could enhance cell proliferation by mainly activating
ERK signaling in intrahepatic cholangiocarcinoma cells
[50]. In the present study, we found ectopic expression in
HGC27 cells activated PI3K/Akt signaling whereas
knockdown of L1cam in SGC7901 cells inhibited Akt
signaling. In addition, the increased cellular motilities
promoted by L1cam could be eliminated by blocking
of PI3K/Akt pathway in gastric cancer cells. Similar
to our results, Min et al. reported Akt signaling is
Figure 3 L1cam promotes cell proliferation, migration and invasion in gastric cancer cell lines. (A) L1cam protein level is increased after
over-expression of L1cam in HGC27 cells and decreased after knockdown of L1cam in SGC7901 cells. (B) and (C) Ectopic expression of L1cam
stimulates cell proliferation in HGC27 cells whereas knockdown of L1cam inhibits cell proliferation in SGC7901 cells as determined by MTT assays (B)
and colony formation assays (C). (D) and (E) Ectopic expression of L1cam stimulates cell motility whereas knockdown of L1cam inhibits cell motility in
gastric cancer cells as determined by migration assays (D) and invasion assays (E). Bars represented mean ± SD of three independent tests, all *P < 0.05.
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cholangiocarcinoma progression [25]; Doberstein et al.
found that L1cam could activate P13K/Akt pathway
to induce cell proliferation and invasion in renal cell
carcinoma [15]. These results suggest that the signaling
pathways activated by L1cam may be tumor specific.
However, further investigation is needed to explore the
underlying molecular mechanism by which L1cam
promotes gastric cancer progression and metastasis.
Conclusions
In the present study, we found L1cam is overexpressed
in gastric cancer cells and tissues. L1cam expression is
associated with aggressive tumor phenotypes and poorsurvival in gastric cancer patients. Overexpression of
L1cam promotes cell proliferation, migration and invasion,
chemoresistanse as well as tumorigenesis and metastasis
via activation of PI3K/Akt signaling pathway in gastric
cancer. Therefore, L1cam expression level could be used
for prediction of cancer progression, metastasis and
prognosis of gastric cancer patients. Targeting L1cam
might be a promising therapeutic strategy for gastric
cancer patients.
Materials and methods
Human tissue specimens and cell lines
A cohort of 156 formalin-fixed, paraffin-embedded tissue
samples collected from gastric cancer patients who
Figure 4 L1cam affects the reponsiveness to oxaliplatin of gastric cancer cells. (A) SGC7901 cells were transfected with sh-L1cam or
sramble lentivirus. Cells were left untreated or administrated with different concentrations of oxaliplatin and cell cycle analyses were performed.
Graph indicates the percentage of cells in sub G1/G0 phase (apoptotic cells), *P <0.05. (B) HGC27 cells were transfected with L1cam or negative
control vectors. Cells were left untreated or administrated with different concentrations of oxaliplatin and cell cycle analyses were performed.
Graph indicates the percentage of cells in sub G1/G0 phase (apoptotic cells), *P <0.05.
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Center (Guangzhou, China) between 2004 and 2006
were retrieved. Fresh gastric cancer tissues and matched
adjacent noncancerous tissues were obtained from 30 of
the 156 patients and stored in liquid nitrogen until use.
All the patients had a histological diagnosis of gastric
cancer. A written informed consent was obtained from
each patient involved in this study and the study protocol
was approved by the ethics committee of Sun Yat-sen
University Cancer Center. All the patients underwent total
or subtotal gastrectomy, none of the patients received any
treatment before surgery. Seventy patients who received
adjuvant chemotherapy after surgery were on the 5-FU,
platinum or taxol-based regimens. Each patient was
followed-up regularly after operation at three-month
interval. The median follow-up time was 30 months
(range: 3 to 112 months). All the clinicopathological
information including age, gender, tumor size, differenti-
ation status, lymph node invasion, venous invasion,
peritoneal dissemination, liver metastasis and TNM stage
were retrieved from patients’ medical records.
Five human gastric cancer cell lines (MKN28, AGS,
SGC7901, HGC27 and BGC823) were obtained from
either the American Type Culture Collection or RIKEN
Cell Bank; cells were cultured and stored according
to providers’ instructions. Cells were routinely authenti-
cated every six months (last examined in September 2012)
by growth curve analysis, cell morphology monitoring and
testing for mycoplasma.
RNA isolation and real-time quantitative RT-PCR analysis
Total RNA was extracted from the tissues and cells with
Trizol reagent (Invitrogen) according to the manufac-
turer’s instructions. The details for reverse transcription of
RNA and real-time PCR are described previously [51].
L1cam mRNA expression were measured using a SYBR
Premix Ex Taq™ kit (Takara); β-actin expression was usedas a reference. The PCR primers for amplifications for






Real-time PCR was carried out with an ABI PRISM®
7500 Seqtence Detection System. The relative level of
L1cam mRNA was normalized to that of β-actin and
calculated by the 2-△△ct method.
Western blot analysis
Western blot analysis was performed according to a stan-
dard method as described previously [52]. For immuno-
blotting of L1cam, a mouse L1cam antibody (sc-33686)
was purchased from Santa Cruz Biotechnology. For detec-
tion of Akt and p-Akt, rabbit antibodies against total Akt
and Ser473 phosphorylated Akt were obtained from Cell
Signaling Technology. A mouse monoclonal α-tubulin
antibody (1:20000; Abcam) was used as loading control.
Immunohistochemistry (IHC) analysis
The paraffin-embedded tissue blocks were cut into 4 μm
slides. A mouse L1cam antibody (sc-33686) was used for
immunostaining. IHC analysis of L1cam was performed
according to a previously described method [53]. To
quantify L1cam protein expression, both the intensity
and extent of immunoreactivity were evaluated and
scored. In the present study, IHC intensity was scored as
follows: 0, negative staining; 1, weak staining; 2, moderate
staining; 3, strong staining. The scores of the extent of
immunoreactivity ranged from 0 to 3 and were according
to the percentage of cells that had positive staining in
each microscopic field of view (0, <25%; 1, 25%-50%;
2, 50%-75%; 3, 75%-100%). A final score ranging from
Figure 5 L1cam promotes gastric cancer cell growth and metastasis in vivo. (A) SGC7901/Scramble and SGC7901/sh-L1cam cells (1 ×
106cells/mouse) were injected subcutaneously into the left and right dorsal flanks of the nude mice (n = 6), tumor volumes were measured on
the indicated days. Data points are presented as mean volume ± SD. (B) Histopathology of xenograft tumors, the tumor sections were under HE
staining and IHC staining for L1cam and Ki-67. (C) SGC7901/Scramble and SGC7901/sh-L1cam cells (2 × 106cells/mouse) were injected into the tail
vein of two groups of nude mice (ten for each group). Six weeks post injection, the mice were killed and the lungs and livers were removed and
paraffin embedded.
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intensity and extent. L1cam expression level was
considered high when the final scores were ≥ 4 and
low when the final scores were < 4.
Vector construction and transfection, lentivirus
production and transduction
To overexpress L1cam, the coding sequence of L1cam
was amplified and subcloned into the pcDNA3.1 (+)
vector (Invitrogen, CA, USA) according to the manufac-
turer’ instructions. HGC27 cells were then transfectedwith a negative control vector or L1cam expressing
plasmid using lipofectamine 2000 (Invitrogen). The result-
ant cells were named HGC27/Vector and HGC27/L1cam
cells, respectively. To generate L1cam stable knockdown
cells, lentivirus containing L1cam short hairpin RNA
(shRNA) or scrambled oligonucleotides were obtained
from GenePharma Biotech (Shanghai, China). An annealed
short interfering RNA (siRNA) for L1cam selected from 3
different target sequences was inserted into the LV-3
(pGLVH1/GFP + Puro) vector. SGC7901 cells were trans-
duced with lentivirus and stable cell lines were selected per
Figure 6 (See legend on next page.)
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Figure 6 PI3K/Akt signaling is involved in L1cam stimulated gastric cancer cell migration and invasion. (A) Western blot analysis of
whole- cell lysates using anti-phospho-Akt (Ser473) or anti-Akt antibody. (B) Western blot analysis in from HGC27 cells expressing L1cam or
empty vector after pretreatment with 20 μM LY294002 for 30 min, using anti-phospho-Akt (Ser473) or anti-Akt antibody. (C) Migratory and
invasive abilities of HGC27 cells expressing L1cam or the empty vector evaluated by Transwell assay after pretreatment with LY294002. (D)
Western blot analysis of whole-cell lysates from HGC27 cells expressing L1cam or the empty vector 24 h after transfection with AKT siRNA or a
scrambled siRNA, using anti-phospho-Akt (Ser473) or anti-Akt antibody. (E) Migratory and invasive abilities of HGC27 cells expressing L1cam or
the empty vector as evaluated by Transwell assay after transfection with Akt siRNA or the scrambled siRNA. (F) SGC7901 cells were injected into
the flank of nude mice, LY294002 (25 mg/kg) were intraperitoneally injected into the nude mice every four days, tumor volumes were measured
at indicated days. (G) Tumors formed by different cells (SGC7901/Scramble or SGC7901/sh-L1cam, SGC7901/DMSO or SGC7901/LY294002) were
collected and protein was extracted. Western blot analysis was conducted to detect the Akt and phospho-Akt level. Photomicrographs are at
100×. Bars correspond to mean ± SD of three independent experiments.
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shRNA were, for sh-L1cam#1, 5′-GGAAATGAGACC
ACCAATA-3′; for sh-L1cam#2, 5′-CAACAGTGCTTCA
GGACGA-3′; for sh-L1cam#3, 5′-CGATGAAAGATGAG
ACCTT-3′. In this study, we used sh-L1cam#1 because it
could effectively knockdown endogenous L1cam in gastric
cancer cell lines based on our preliminary experiments.
The target sequence for scrambled shRNA was 5′-GTCT
CCACGCGCAGTACATTT-3′. The cell lines stably
expressing L1cam shRNA or scrambled oligonucleotides
were designated as SGC7901/sh-L1cam and SGC7901/
scramble cells, respectively.
Cell proliferation assays
The 3-(4, 5-dimethylthiazole-2-yl)-2, 5-biphenyl tetrazolium
bromide (MTT) assay was performed to test cell viability
and proliferation. The spectrophotometric absorbance at
570 nm was measured for each sample, all the experiments
were repeated 3 times in triplicate and the mean was
calculated.
For the colony formation assay, 500 cells were placed
in a six-well plate and cultured for 14 days with RPMI
1640 medium (GIBCO) containing 10% FBS. Colonies
were fixed with methanol and stained with 0.1% crystal
violet (1 mg/ml).
In vitro invasion and migration assay
The cell invasive and migratory potential was evaluated
using transwell chambers (8 μm pore; BD Biosciences).
For the invasion assay, 1 × 105 cells suspended in 100 μl
serum-free medium were added to the upper chamber
of the inserts, which were coated with a mitrigel mix;
fetal bovine serum (500 μl) was added to the lower
chamber as a chemoattractant. After incubation for
24 hours, non-invading cells on the upper surface were
wiped off with a cotton swab and cells that invaded to
the lower side of the membrane were fixed with methanol,
stained with 0.1% crystal violet, air dried and photographed.
For the migration assay, tumor cells (5 × 104 cells in 100 μl
serum-free medium) were placed in the top chamber of
each insert without matrix gel, and 500 μl fetal bovine
serum was added to the lower compartment. 16 hourslater, the cells on the upper side were removed, and
the cells that migrated to the lower chamber were fixed and
stained with crystal violet. The number of invading or
migrating cells was determined by microscopically counting
five different fields.
Cell cycle analysis
Cells were seeded in six-well plates and cultured for
12 hours, and then cells were left untreated or treated
with different concentrations of oxaliplatin (10 μg/mL or
20 μg/mL) for 24 hours. Afterward, cells were collected
and washed with phosphate-buffered saline, cell cycle
analysis was carried out as previously described [54].
In vivo proliferation and metastasis assays
Female BABL/c athymic nude mice (four to five weeks old)
were obtained from the Animal Center of Guangdong
province (Guangzhou, China). All the animal experiments
were performed according to the National Institutes of
Health animal use guidelines on the use of experimental
animals.
To evaluate the in vivo proliferative effect of L1cam,
the SGC7901/Scramble and SGC7901/sh-L1cam cells
(1 × 106 cells/mouse) were injected subcutaneously into
the left and right dorsal flanks of the nude mice. Tumor
size was measured every four days and tumor volume
was estimated. After five weeks, the mice were sacrificed
and the tumors were dissected out. Tumor tissues
were fixed with 10% formalin and embedded in paraf-
fin. Representative tumor sections were obtained from
paraffin-embedded tumor tissue and stained with
haematoxylin-eosin (H&E) or specific antibodies.
To investigate the effect of L1cam on tumor metastasis,
the SGC7901/Scramble and SGC7901/sh-L1cam cells
(2 × 106 cells/mouse) were injected into the tail vein of
two groups of nude mice (ten for each cell group). Six
weeks post injection, the mice were sacrificed and the
lungs and livers were removed and paraffin embedded.
Consecutive sections (4 μm) were made and stained with
haematoxylin-eosin. The micro-metastases in the lungs
and livers were examined and counted under a dissecting
microscope as described previously [55].
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LY294002, a specific inhibitor of PI3K, was purchased
from Cell Signaling Technology. For administration of
LY294002, tumor cells were incubated with 50 μM
LY294002 (Cell Signaling Technology) for one hour
before performing in vitro assays. Small-interfering RNA
(siRNA) targeting Akt and a scrambled siRNA were
purchased from Ribobio (Guangzhou, China). The target
sequence for AKT siRNA is 5′-GCACCTTCATTGGC
TACAA-3′, and the target for scrambled siRNA is 5′-
CGTACGCGGAATACTTCGA-3′. For siRNA transfec-
tion, cells were plated in a six-well plate the day before
transfection. Twenty-four hours later, cells were transfected
with 50 nM siRNAs using lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions. The efficiency
of gene silencing was confirmed by immunoblotting.
Migration and invasion assays were performed twenty-four
hours after siRNA transfection in gastric cancer cells.
To evaluate the in vivo effect of LY294002, SGC7901
cells were subcutaneously implanted into the flank of
nude mice, Seven days later, LY294002 (25 mg/kg)
were intraperitoneally injected into the nude mice
every four days. The tumor volume was measured
every four days. The mice were sacrificed after
5 weeks and the tumors were dissected out.
Statistical analysis
Statistical analysis was performed using the SPSS software
package (version 16.0, SPSS Inc). Statistical significance
was tested by a Student’s t-test or a Chi-square test as
appropriate. Survival analysis was performed using the
Kaplan-Meier method, and the log-rank test was used
to compare the differences between patient groups.
Parameters with a P value < 0.05 by univariate analysis
were subject to multivariate analysis using the Cox
proportional hazards model to identify independent
prognostic factors for gastric cancer patients. All
differences were statistically significant with a value of
P < 0.05.
Additional file
Additional file 1: Figure S1. Kaplan-Meier analysis of overall survival
based on Therapeutic strategies in 156 gastric cancer patients.
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